Regeneron Pharmaceuticals, Inc.
NasdaqGS-REGN
Company Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Name
Regeneron Pharmaceuticals, Inc.
CEO
Dr. Leonard S. Schleifer M.D., Ph.D.
Website
www.regeneron.com
Sector
Biotechnology
Year Founded
1988
Profile
Market Cap
$123.2B
EV
$108.37B
Shares Out
107.93M
Revenue
$13.49B
Employees
13,926
Margins
Gross
53.27%
EBITDA
33.5%
Operating
30.14%
Pre-Tax
34.01%
Net
32.04%
FCF
24.68%
Returns (5Yr Avg)
ROA
21.11%
ROTA
29.42%
ROE
29.19%
ROCE
26.65%
ROIC
30.74%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
$1,162.19
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$9,809M
Net Debt
-$14.83B
Debt/Equity
0.1
EBIT/Interest
60.69
Growth (CAGR)
Rev 3Yr
2.89%
Rev 5Yr
15.57%
Rev 10Yr
18.37%
Dil EPS 3Yr
-11.97%
Dil EPS 5Yr
15.97%
Dil EPS 10Yr
26.59%
Rev Fwd 2Yr
8.24%
EBITDA Fwd 2Yr
5.54%
EPS Fwd 2Yr
5.65%
EPS LT Growth Est
19%
Dividends
Yield
—
Payout
—
DPS
—
DPS Growth 3Yr
—
DPS Growth 5Yr
—
DPS Growth 10Yr
—
DPS Growth Fwd 2Yr
—